Showing results (61-70 of 94) with videos related to

Sort By:
Pageof 10
Plos One|March 21, 2020
Assessment of clinical outcomes with immune checkpoint inhibitor therapy in melanoma patients with CDKN2A and TP53 pathogenic mutationsThomas T DeLeon, Daniel R Almquist, Benjamin R Kipp, et al.
NPJ Precision Oncology|August 6, 2021
A phase I/II study of rovalpituzumab tesirine in delta-like 3-expressing advanced solid tumorsAaron S Mansfield, David S Hong, Christine L Hann, et al.
The Oncologist|November 20, 2020
Tumor Frameshift Mutation Proportion Predicts Response to Immunotherapy in Mismatch Repair-Deficient Prostate CancerLaura A Sena, Julia Fountain, Pedro Isaacsson Velho, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 25, 2026
Carboplatin, Cabazitaxel and Abiraterone in High-Volume Metastatic Castration-Sensitive Prostate Cancer: The CASCARA Phase 2 StudyEmmanuel S Antonarakis, Qing Cao, Victoria Catharine, et al.
The Prostate|April 1, 2021
Comparison of germline mutations in African American and Caucasian men with metastatic prostate cancerElisa M Ledet, Earle F Burgess, Alexandra O Sokolova, et al.
JAMA Network Open|July 22, 2021
Association of Concomitant Bone Resorption Inhibitors With Overall Survival Among Patients With Metastatic Castration-Resistant Prostate Cancer and Bone Metastases Receiving Abiraterone Acetate With Prednisone as First-Line TherapyEdoardo Francini, Francesco Montagnani, Pier Vitale Nuzzo, et al.
European Urology Oncology|March 24, 2024
Three- and Seven-month Prostate-specific Antigen Levels as Prognostic Markers for Overall Survival in Metastatic Hormone-sensitive Prostate Cancer: Results from SWOG S1216, a Phase 3 Randomized Trial of Androgen Deprivation Plus Orteronel or BicalutamideMamta Parikh, Catherine Tangen, Maha H A Hussain, et al.
European Urology|January 23, 2025
Heterogeneity of the Treatment Effect with PARP Inhibitors in Metastatic Castration-resistant Prostate Cancer: A Living Interactive Systematic Review and Meta-analysisSyed Arsalan Ahmed Naqvi, Irbaz Bin Riaz, Arifa Bibi, et al.
The Prostate|November 16, 2022
Differential responses to taxanes and PARP inhibitors in ATM- versus BRCA2-mutated metastatic castrate-resistant prostate cancerChristopher T Su, Emily Nizialek, Jacob E Berchuck, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 30, 2023
Randomized Phase III Study of Enzalutamide Compared With Enzalutamide Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer (Alliance A031201 Trial)Michael J Morris, Glenn Heller, David W Hillman, et al.
Pageof 10